Response to Methodological and reporting considerations for reflex FGFR testing in urinary tract carcinomas

View at publisher Summarise with VIRAT
Authors: Ngoc-Nhu Jennifer Nguyen, Ekaterina Olkhov‐Mitsel, Kenneth J. Craddock, Trevor A. Flood, Michelle R. Downes
Cited by: 0
References: 3

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Dear correspondence author(s), We would like to express our appreciation for your interest in our work1 and for your constructive feedback, which enriches discussions about biomarker testing in urinary tract carcinomas. We thank you for noticing the numerical errors in the manuscript, all of which represent transcription errors. The sentence in the “Abstract” reporting the association between actionable FGFR alterations and the tumor site should read as follows: “The prevalence of actionable FGFR alterations was statistically significantly higher in upper vs lower tract carcinomas (22.2% vs 10.0%, P = .007)” (the corrected numbers are in bold). The numbers and percentages for actionable (tier 1 or 2) FGFR alterations and those for any (tier 1, 2, or 3) FGFR alterations in upper vs lower urinary tract carcinomas provided in original Table 2 are correct. Of note, upper tract carcinomas consist of tumors originating from the renal pelvis or ureter, while lower tract carcinomas arise from the bladder or urethra. In original Table 1, the number of patients 55 years of age or older should indeed read 349, not 34 (see Table 1 corrigendum). This distribution reflects the underlying epidemiology of the disease rather than sampling bias. Although the smaller size of the group of patients younger than 55 years of age may limit power for age-stratified comparisons only and age-stratified comparisons, age was not the primary variable of interest. In original Figure 1, the number of actionable FGFR2 variants should be 3 instead of 2 (see Figure 1 corrigendum). Statistical analyses were performed on accurate numbers; hence, the provided P values and the conclusions remain unchanged and valid.

Fields of Study & Subjects

Bladder and Urothelial Cancer Treatments Fibroblast Growth Factor Research Cancer Genomics and Diagnostics

Publication details

Journal / source
American Journal of Clinical Pathology
Volume
165
Issue
3
Publication date
1 March 2026
Language
EN